BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17441963)

  • 1. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.
    Temmink OH; Emura T; de Bruin M; Fukushima M; Peters GJ
    Cancer Sci; 2007 Jun; 98(6):779-89. PubMed ID: 17441963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
    Temmink OH; Prins HJ; van Gelderop E; Peters GJ
    Br J Cancer; 2007 Jan; 96(1):61-6. PubMed ID: 17179993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiosensitization by thymidine phosphorylase inhibitor in thymidine phosphorylase negative and overexpressing bladder cancer cell lines.
    El-Naggar M; Ebbing E; Bijnsdorp I; van den Berg J; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):413-21. PubMed ID: 24940699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies.
    Chakrabarti S; Wintheiser G; Tella SH; Oxencis C; Mahipal A
    Pharmacol Ther; 2021 Aug; 224():107823. PubMed ID: 33667525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review on TAS-102 development and its use for metastatic colorectal cancer.
    Mota JM; Fonseca LG; Braghiroli MI; Hoff PM
    Crit Rev Oncol Hematol; 2016 Aug; 104():91-7. PubMed ID: 27296058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAS-102: a novel antimetabolite for the 21st century.
    Uboha N; Hochster HS
    Future Oncol; 2016 Jan; 12(2):153-63. PubMed ID: 26616466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel antimetabolite: TAS-102 for metastatic colorectal cancer.
    Miyamoto Y; Lenz HJ; Baba H
    Expert Rev Clin Pharmacol; 2016; 9(3):355-65. PubMed ID: 26677869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
    Chan BM; Hochster HS; Lenz HJ
    Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies.
    van der Velden DL; Opdam FL; Voest EE
    Clin Cancer Res; 2016 Jun; 22(12):2835-9. PubMed ID: 27126991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
    Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
    Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination.
    Roviello G; Fancelli S; Gatta Michelet MR; Aprile G; Nobili S; Roviello F; Cianchi F; Mini E; Lavacchi D
    Crit Rev Oncol Hematol; 2020 Aug; 152():102987. PubMed ID: 32485527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil.
    Becerra CR; Yoshida K; Mizuguchi H; Patel M; Von Hoff D
    J Clin Pharmacol; 2017 Jun; 57(6):751-759. PubMed ID: 28070894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
    Yoshino T; Kojima T; Bando H; Yamazaki T; Naito Y; Mukai H; Fuse N; Goto K; Ito Y; Doi T; Ohtsu A
    Cancer Sci; 2016 May; 107(5):659-65. PubMed ID: 26918279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Nukatsuka M; Nakagawa F; Takechi T
    Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
    Emura T; Nakagawa F; Fujioka A; Ohshimo H; Kitazato K
    Oncol Rep; 2004 Feb; 11(2):381-7. PubMed ID: 14719072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAS-102, a novel antitumor agent: a review of the mechanism of action.
    Lenz HJ; Stintzing S; Loupakis F
    Cancer Treat Rev; 2015 Nov; 41(9):777-83. PubMed ID: 26428513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
    Emura T; Murakami Y; Nakagawa F; Fukushima M; Kitazato K
    Int J Mol Med; 2004 Apr; 13(4):545-9. PubMed ID: 15010854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells.
    Temmink OH; de Bruin M; Comijn EM; Fukushima M; Peters GJ
    Anticancer Drugs; 2005 Mar; 16(3):285-92. PubMed ID: 15711180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
    Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Dadduzio V; Salvatore L; Borelli B; Pietrantonio F; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Loupakis F; Lenz HJ
    Eur J Cancer; 2017 Nov; 86():197-206. PubMed ID: 28992563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed.
    Hernando-Cubero J; Matos-García I; Alonso-Orduña V; Capdevila J
    J Gastrointest Cancer; 2017 Jun; 48(2):135-147. PubMed ID: 28397102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.